Strides Pharma reports Rs. 2,489.7 crore revenue during FY26, 2% YoY growth

Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million

Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore

The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

Neuland Laboratories posts blockbuster FY26 performance

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore

The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year